<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04735601</url>
  </required_header>
  <id_info>
    <org_study_id>S20-161</org_study_id>
    <nct_id>NCT04735601</nct_id>
  </id_info>
  <brief_title>Ahmed Valve Implantation Coated With Poly Lactic -Co-glycolic Acid (PLGA) Saturated With Mitomycin-C in the Management of Adult Onset Glaucoma in Sturge Weber Syndrome</brief_title>
  <official_title>Ahmed Valve Implantation Coated With Poly Lactic -Co-glycolic Acid (PLGA) Saturated With Mitomycin-C in the Management of Adult Onset Glaucoma in Sturge Weber Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sohag University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sohag University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sturge weber's syndrome is an oculcutaneous syndrome, ocular manifestations may include&#xD;
      heamangioma in the eye lids, choroidal heamangioma, or glaucoma, the glaucoma may present at&#xD;
      infancy and may be due to resistance to aqueous outflow through trabecular meshwork(1), it&#xD;
      may develop later and this is due to episcleral venous raised pressure.(2-3) Glaucoma&#xD;
      associated with Sturge weber syndrome is difficult to be treated medically with high risk of&#xD;
      complications when treated with bleb -based surgeries. Suprachoroidal hemorrhage or&#xD;
      detachment is a challenging complication which must be encountered.&#xD;
&#xD;
      The usage of Ahmed valve in the management of glaucoma associated with Sturge weber syndrome&#xD;
      is a bleb based procedure carries the risks of over filtration or encapsulation and decreased&#xD;
      filtration with failure to control glaucoma.&#xD;
&#xD;
      The use of Ahmed valve in the management of pediatric glaucoma associated with Sturge weber&#xD;
      syndrome has better results as recorded by Nassiri et al. Ahmed valve implantation can have&#xD;
      some drawbacks such as pupillary irregularity, lens opacification, or encapsulation.(4-7)&#xD;
      Glaucoma drainage devices such as Ahmed valve, Molteno or Braeveldt valve can be used when&#xD;
      other methods of treatment fail, they provide alternative pathway to the aqueous to be&#xD;
      collected in a plate positioned under the conjunctiva, (8-10) Encapsulation is a major&#xD;
      problem occurs around the end plate due to fibrous reaction and so the drainage of the&#xD;
      aqueous is decreased , Epatein (11) attributed that to fibro vascular proliferation in the&#xD;
      episcleral tissue .the fibrous reaction is multifactorial , it may be due to the size of the&#xD;
      end plate, the biomaterial, design or the shape of the plate.&#xD;
&#xD;
      The use of drainage devices with advanced drug delivery system can improve the success of&#xD;
      drainage device.&#xD;
&#xD;
      A double-layered porous coating for Ahmed glaucoma valves based on biodegradable&#xD;
      poly(lactic-co-glycolic acid) (PLGA) was described by Ponnusamy et al. [12] to produce&#xD;
      continuous release of antifibrotic agents [mitomycin C (MMC) and/or 5-fluorouracil (5-FU)] to&#xD;
      the subconjunctival space. This release continue for about one month with decreasing&#xD;
      fibrosis, the nanofiltration membrane could entrap the proteins passing out from the anterior&#xD;
      chamber leading to minimal increase in aqueous resistance.(12-13)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All participants will be evaluated regarding the following:&#xD;
&#xD;
      Visual acuity (VA) will be measured before and after surgery. Visual field (VF) will be&#xD;
      assessed. Optical coherence topography (OCT) Ahmed valve coated with PLGA nanoparticles&#xD;
      saturated with Mitomycin-C 2mg/ml. Follow up will continue for one year regarding intraocular&#xD;
      pressure IOP, VA , VF, OCT and occurrence of complications such as erosion, extrusion,&#xD;
      infection, encapsulation and fibrosis around the stent.&#xD;
&#xD;
      Data will be collected and analyzed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">May 15, 2021</start_date>
  <completion_date type="Anticipated">August 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 15, 2021</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>IOP in mmg</measure>
    <time_frame>one year</time_frame>
    <description>efficacy of Ahmed valve implantation coated with PLGA sturated with MMC</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of complications</measure>
    <time_frame>one year</time_frame>
    <description>to assess complications regarding the flap , erosions to the conjunctiva , extrusion , endothelial toxicity.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Glaucoma</condition>
  <arm_group>
    <arm_group_label>Ahmed valve coated with PLGA is implanted in secondary glaucoma in Sturge Weber syndrome</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ahmed valve coated with PLGA is implanted in secondary glaucoma in Sturge Weber syndrome</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ahmed valve implanted in secondary glaucoma in Sturge Weber syndrome</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ahmed valve will be implanted alone with no PLGA</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Ahmed Valve</intervention_name>
    <description>Ahmed valve implantation coated with poly lactic -co-glycolic acid (PLGA) saturated with Mitomycin-C in the management of adult onset glaucoma in Sturge Weber syndrome</description>
    <arm_group_label>Ahmed valve coated with PLGA is implanted in secondary glaucoma in Sturge Weber syndrome</arm_group_label>
    <arm_group_label>Ahmed valve implanted in secondary glaucoma in Sturge Weber syndrome</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients suffered from adult onset Sturge Weber syndrome and subjected to Ahmed valve&#xD;
             implantation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  other ocular pathology; choroidal heamangioma, cataract, exudative retinal detachment.&#xD;
&#xD;
        Patients under 18 years old&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hany Mahmoud, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sohag University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hany Mahmoud, MD</last_name>
    <phone>01024368111</phone>
    <email>drhanymahmoud@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hany Mahmoud, MD</last_name>
    <phone>01024368111</phone>
    <email>drhanymahmoud@med.sohag.edu.eg</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sohag University</name>
      <address>
        <city>Sohag</city>
        <zip>82524</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hany Mahmoud</last_name>
      <phone>01024368111</phone>
      <email>drhanymahmoud@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>January 23, 2021</study_first_submitted>
  <study_first_submitted_qc>February 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 3, 2021</study_first_posted>
  <last_update_submitted>March 19, 2021</last_update_submitted>
  <last_update_submitted_qc>March 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sohag University</investigator_affiliation>
    <investigator_full_name>Hany Mahmoud</investigator_full_name>
    <investigator_title>principal investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sturge-Weber Syndrome</mesh_term>
    <mesh_term>Brain Stem Infarctions</mesh_term>
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Klippel-Trenaunay-Weber Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>one year</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

